Pathological vascular remodeling and cardiac hypertrophy [18], [19], [20], [21] can be treated with AT1R blocking (ARB) drugs, thus suggesting that activated AT1R contributes to changes in the phenotype of cells in vivo. This evidence concerns the gene AGTR1 and cardiac hypertrophy.